How effective are semaglutide tablets for weight loss?

What the trial numbers actually mean, and how to read them honestly

The OASIS 4 trial enrolled 307 adults without diabetes who had obesity or overweight alongside at least one weight-related condition. Over 64 weeks, participants taking the 25mg oral semaglutide dose lost an average of about 13.6% of body weight. The placebo group lost around 2.4%. That gap (more than 11 percentage points) is clinically meaningful, and the finding held up even when the analysis included participants who stopped taking the tablet early.

The ~16.6% figure requires context. It comes from a per-protocol analysis of people who followed the treatment schedule precisely, stayed on the full maintenance dose and completed the study. It is a real number from real participants, but framing it as the headline result would misrepresent what an average person starting treatment should expect. Both figures are worth knowing; neither should be treated as a promise.

These results were central to the MHRA's decision to approve Wegovy tablets on 11 June 2026. As announced by the MHRA, the UK became the first country in Europe to license an oral GLP-1 medicine for weight management, a detail that places this treatment at the front of a new category rather than at the back of an established one. For a fuller comparison with the injectable version, the Wegovy pill versus injection page works through the evidence side by side.

The most common side effects reported in OASIS 4 were gastrointestinal: nausea, diarrhoea and vomiting in particular. They affected around 74% of the oral semaglutide group versus 42% on placebo, though most were mild to moderate and tended to ease as the body adjusted. That GI rate is worth knowing before starting, not to discourage anyone, but because slow titration through the dose schedule exists precisely to reduce it.

How the dosing schedule shapes what you actually lose

Semaglutide tablets for weight loss follow a four-step escalation: 1.5mg, then 4mg, then 9mg, then the 25mg maintenance dose, with at least a month at each level before moving up. The climb is intentional. Rushing it tends to produce more side effects and no better results; the slow escalation is how the tablet earns its effectiveness figures.

A question our prescribers hear most weeks is whether patients already stable on the 2.4mg weekly injection can switch straight to the tablet. The answer, per the prescribing information, is yes, patients established on injectable semaglutide 2.4mg may move directly to the 25mg tablet, subject to clinical assessment. That flexibility matters for people who want the convenience of a daily tablet without restarting a long titration from scratch.

Taking the tablet correctly also directly affects how much semaglutide is absorbed. Oral semaglutide is co-formulated with an absorption enhancer called SNAC, but the stomach environment still needs to be right. It must be taken first thing in the morning, swallowed whole with a small amount of plain water (up to around 120ml), and at least 30 minutes must pass before any food, other drink or additional oral medicines. Coffee counts. Missing that window even occasionally reduces absorption and, over time, may reduce the weight-loss effect. The semaglutide oral tablets guide covers the practical steps in more detail.

Unlike the injectable pen, the tablet needs no refrigeration. That single fact removes a meaningful barrier for people who travel frequently or simply find cold-chain storage inconvenient.

How oral semaglutide's results sit against the broader landscape

Placing 13.6% average weight loss in context: the STEP 1 trial of injectable semaglutide 2.4mg (Wegovy injection) reported around 15% average loss over 68 weeks, as published in the New England Journal of Medicine. The oral tablet's headline figure is modestly lower, which is consistent with the pharmacology, oral bioavailability is inherently lower than subcutaneous absorption, even with an enhancer.

That said, a 13.6% average reduction in body weight is not a marginal result. For someone weighing 100kg, it represents roughly 13–14kg lost. At the adherent-participant level (~16.6%), the gap with the injection narrows considerably. Whether the injection or the tablet is more suitable is a clinical question that depends on individual preference, tolerance and medical history, not on the trial headline alone. Those thinking about the distinction between Wegovy tablets and Rybelsus should note that Rybelsus is licensed for type 2 diabetes management, not weight loss; the two products use different dose ranges and indications entirely.

For adults considering private treatment, understanding the cost picture alongside the effectiveness data is reasonable. The Wegovy pill cost page sets out what private treatment typically involves financially. And for anyone not yet sure which treatment fits their situation, the weight-loss treatment options page is a practical starting point before a consultation.

What the evidence cannot tell you, and what a prescriber can

Clinical trial data describes populations. It tells you what happened on average across hundreds of people who met specific inclusion criteria, followed a structured protocol and were monitored closely. It does not predict your result. Variables including starting weight, adherence, diet quality, physical activity, other medicines and individual physiology all shape what actually happens for a specific person on a specific treatment.

This is not a reason to dismiss the evidence, the OASIS 4 numbers are robust, from a well-designed phase-3 trial, and were sufficient for MHRA approval. It is a reason to pair the evidence with clinical assessment. A prescriber can review your health history, identify any conditions that affect suitability, guide you through dose escalation and adjust the plan if your response differs from the trial average.

Wegovy tablets are a prescription-only medicine. The licensed route in the UK is through a prescriber who has assessed your individual circumstances. For an overview of how the tablets work mechanically before a consultation, the semaglutide tablets page covers the mechanism in plain terms. If you are ready to discuss whether this treatment suits you, start your free consultation with our prescribers.